Low-dose NOAC linked to lower bleeding rates vs triple therapy in patients with Afib having PCI
Access to the full content of this site is available only to registered healthcare professionals.
Register to read more
Patients with atrial fibrillation (Afib) having percutaneous coronary intervention have less clinically significant bleeding with low- or very-low-dose rivaroxaban combination therapies vs triple therapy with vitamin K antagonist.
Why this matters
Usual therapy is vitamin K antagonist+dual antiplatelet therapy (DAPT: P2Y12 inhibitor and aspirin), but relative efficacy and safety of rivaroxaban, a novel oral anticoagulant, are unclear.
Rivaroxaban groups had significantly less bleeding vs standard triple-therapy groups (16.8%, 18.0% vs 26.7% with triple therapy; HRs with rivaroxaban 0.59, 0.63; P<.001 for both comparisons).
Outcomes were similar among the 3 treatment groups for cardiovascular, myocardial infarction, and stroke deaths.
21.0% of low-dose rivaroxaban, 21.1% very-low-dose rivaroxaban, 29.4% triple-ther...